Affordable Access

deepdyve-link
Publisher Website

Combined elevation of TRIB2 and MAP3K1 indicates poor prognosis and chemoresistance to temozolomide in glioblastoma.

Authors
  • Wang, Jia1, 2
  • Zuo, Jie3
  • Wahafu, Alafate1
  • Wang, Mao-de1, 2
  • Li, Rui-Chun1
  • Xie, Wan-Fu1
  • 1 Department of Neurosurgery, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China. , (China)
  • 2 Center of Brain Science, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China. , (China)
  • 3 The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China. , (China)
Type
Published Article
Journal
CNS Neuroscience & Therapeutics
Publisher
Wiley (Blackwell Publishing)
Publication Date
Mar 01, 2020
Volume
26
Issue
3
Pages
297–308
Identifiers
DOI: 10.1111/cns.13197
PMID: 31318172
Source
Medline
Keywords
Language
English
License
Unknown

Abstract

Glioblastoma (GBM) is the most lethal primary malignant brain tumor in adults with poor survival due to acquired therapeutic resistance and rapid recurrence. Currently, the standard clinical strategy for glioma includes maximum surgical resection, radiotherapy, and temozolomide (TMZ) chemotherapy; however, the median survival of patients with GBM remains poor despite these comprehensive therapies. Therefore, the identification of new prognostic biomarkers is urgently needed to evaluate the malignancy and long-term outcome of glioma. To further investigate prognostic biomarkers and potential therapeutic targets for GBM. In this study, we identified tribbles pseudokinase 2 (TRIB2) as one of the genes that is most correlated with pathological classification, radioresistance, and TMZ resistance in glioma. Additionally, the expression of mitogen-activated protein kinase kinase kinase 1 (MAP3K1) showed a strong correlation with TRIB2. Moreover, a combined increase in TRIB2 and MAP3K1 was observed in GBM and indicated a poor prognosis of patients with glioma. Finally, enriched TRIB2 expression and MAP3K1 expression were shown to be associated with resistance to TMZ and radiotherapy. Combined elevation of TRIB2 and MAP3K1 could be novel prognostic biomarkers and potential therapeutic targets to evaluate the malignancy and long-term outcomes of GBM. © 2019 The Authors. CNS Neuroscience & Therapeutics Published by John Wiley & Sons Ltd.

Report this publication

Statistics

Seen <100 times